Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancerJun‐Eul Hwang, Ik‐Joo Chung, Hyeon-Jong Kim et al.|Journal of Cancer Research and Clinical Oncology|2019Cited by 23
The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysisJun‐Eul Hwang, Ik-Joo Chung, Myung Seo Ki et al.|Oncotarget|2017Cited by 4
658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancerPaul Rhee, Michael Chisamore, Byoung Yong Shim et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2
Successful Treatment of Necrotizing Fasciitis in a Patient with Rheumatoid ArthritisJun‐Eul Hwang, Yong-Wook Park, Sang-Ho Kim et al.|Unknown|2006Cited by 1
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.Do‐Youn Oh, Young Su Noh, Min-Hee Ryu et al.|Journal of Clinical Oncology|2025Cited by 0